 --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis on track for mid-2021-- 